TCM Syndrome Differentiation Decoction
Phase 3Small molecule
TCM Syndrome Differentiation Decoction is one of 102 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Geodon
PfizerApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Primacor
SanofiApproved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Midamor
PPadagis LLC
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Cagrilintide
Novo NordiskPhase 3
Pelacarsen
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetes Mellitus1 trial
Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study
Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07121088·3,666 enrolled
Cardiovascular Disease1 trial
Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study
Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07088523·4,205 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details